BioCentury Podcasts

•

Canal • 2 programas

Ciencias de la vida

Ciencias de la vida

Semanal
Ciencias de la vida

Ciencias de la vida

Quincenal

14 ABR

Ep. 360 - FDA’s FIH plans. Plus: billion-dollar deals, funds

A pathway proposed by FDA to cut the time it takes biopharma companies to get to first-in-human trials is more ambitious than similar policies in Australia, China and the U.K. On the latest BioCentury This Week podcast, BioCentury’s analysts assess the proposal, as well as a concession for the biopharma industry on first-in-human studies in PDUFA reauthorization negotiations with FDA. The analysts also discuss the latest pair of billion-dollar biotech deals: Gilead's $3.2 billion takeout of antibody-drug conjugate company Tubulis and the acquisition of Soleno by Neurocrine for $2.9 billion for its Prader-Willi asset. Finally, BioCentury’s analysts discuss the new $6.3 billion Blackstone Life Sciences fund and the €1 billion vehicle unveiled last week by European VC Jeito Capital. This episode of the BioCentury This Week podcast was brought to you by IQVIA Biotech. View full story: https://www.biocentury.com/article/659127 #FDA #FirstInHuman #BiotechMergers #BiotechInvesting #LifeSciencesVC 00:01 - Sponsor Message: IQVIA Biotech 03:24 - FDA First-in-Human 11:44 - America First PDUFA Policy 17:43 - Gilead Buying Tubulis 23:41 - Blackstone's New Fund 28:37 - Jeito Capital 30:44 - Parker Institute To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

14 abr

•

34 min
7 ABR

Ep. 359 - 2Q markets preview, tariffs and biotech takeouts

Biotech has been resilient as the financial markets teeter under global volatility. For now, M&A and financings, if not IPOs, are continuing, but will the Mideast conflict halt biotech’s recovery? On the latest BioCentury This Week podcast, BioCentury’s Stephen Hansen breaks down the near-term and long-term outlook for a biotech industry hoping to continue the growth of 2H25. BioCentury’s analysts also discuss the impact of the Trump administration’s tariffs on the biopharma industry and last week’s biggest deals: the pending $6.3 billion takeout of Centessa by Eli Lilly and the proposed $5.6 billion acquisition of Apellis by Biogen. This episode of the BioCentury This Week podcast was brought to you by IQVIA Biotech. Register now as a delegate or apply to join the 2026 Presenting Company Class before the 26th Bio€quity Europe May 4-6 in Prague sells out. View full story: https://www.biocentury.com/article/659040 #BiotechMarkets #BiotechMA #GlobalVolatility #DrugPricingPolicy #BiopharmaStrategy 00:01 - Sponsor Message: IQVIA Biotech 05:09 - 2Q26 Preview 17:09 - Pharma Tariffs 24:04 - C-Path Initiative 26:32 - Lilly Deal 32:19 - Biogen Deal To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

7 abr

•

39 min
2 ABR

Ep. 358 - Europe's biotech challenge

Biotech innovators around the world are finding speed to be the driver for investment and partnering — speed to early human data and speed to de-risk assets. The new momentum from Asia, in particular China, has added a fresh challenge for European biotech on top of falling equity and R&D investment in Europe and a complex drug pricing landscape. On a special edition of the BioCentury This Week podcast on the eve of the 26th Bio€quity Europe conference, EQT Life Sciences' Christoph Broja and Prague Bio CEO Petra Kinzlová join BioCentury’s analysts to discuss the challenges faced by European biotech today and what the best strategy is to compete in this new era. Kinzlová also describes a growing biotech ecosystem in the Czech Republic, which will host Bio€quity Europe May 4-6. View full story: https://www.biocentury.com/article/659002 #EuropeanBiotech #ClinicalDevelopmentSpeed #ChinaBiotech #DrugPricing #BiotechInvestment 01:10 - Bio€quity Europe Preview 04:32 - Czech Innovation Hubs 09:52 - Pricing, Trials, Funding 13:07 - Fixing Trial Bottlenecks 17:49 - Pension Capital and Risk To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

2 abr

•

24 min
24 MAR

Ep. 356 - Arrowhead’s arc. Plus: AI in biotech venture, Synnovation, MFN

After 20 years of platform building and resets, Arrowhead Pharmaceuticals is making a bid to become a large-cap biotech. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss how the company has built a pipeline and set of enabling technologies that could enable a steep period of value creation based on RNAi. The team then analyzes the $2 billion deal between Synnovation and Novartis for a pan-mutant-selective PI3Kα inhibitor. The analysts also assess where AI is integrating into the biotech venture funnel and provide insights into ultra-rare disease advocacy, FDA’s search for a successor to CBER Director Vinay Prasad, and the Trump administration’s most-favored nation (MFN) drug pricing policy. View full story: https://www.biocentury.com/article/658892 #RNAiTherapeutics #BiotechMA #PI3KAlpha #AIDrugDiscovery #DrugPricingPolicy 00:00 - Introduction 01:14 - Bio€quity Europe 05:33 - Arrowhead 16:49 - Synnovation Novartis 20:00 - AI in Biotech Venture 27:07 - Rare Disease Advocacy 31:22 - MFN Pricing Policy To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

24 mar

•

34 min
27 ENE

Ep. 347 - Speeding China's Innovation. Plus: Neuro Catalysts and Newcos

New rules in China will accelerate the country’s cell and gene therapy sector by reshaping how investigator-initiated trials are conducted and commercialized. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the new framework and why it will create a powerful incentive for deploying new gene and cell therapies. Executive Editor Selina Koch discusses which milestones she is watching in neurology in the year ahead, from psychedelics to Alzheimer's disease. Finally, Senior Biopharma Analyst Danielle Golovin discusses a pair of stories from BioCentury’s Emerging Company Profile series: one focused on Yale spinout Bexorg Inc., which is rethinking CNS drug discovery with a whole-human-brain model, and another on Elkedonia S.A.S., a French start-up aiming at ELK1 to reboot neuroplasticity in depression. View full story: https://www.biocentury.com/article/658189 00:00 - Introduction 03:14 - Speeding China's Innovation 10:36 - Neuro Catalysts 22:01 - Newcos To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

27 ene

•

30 min
17 MAR

Ep. 355 - Capital market mood, Xenon data, Friedreich ataxia pipeline

Biotechs have been pricing follow-ons at a steady pace, with some companies parlaying data into upsized deals, and others even beginning to debut on NASDAQ — but will geopolitical tensions and war in the Middle East scuttle the forward momentum? On the latest BioCentury This Week podcast, BioCentury’s analysts take the temperature of the markets for biotech." They also discuss last week’s late-stage epilepsy data from Xenon Pharmaceuticals, which revived the biotech’s stock and the Kv7 target. And, in a Rare Disease Spotlight, BioCentury’s analysts discuss how Friedreich ataxia is moving into a mechanistic second act, with biotechs pivoting from stabilizing the mitochondrial damage caused by frataxin loss to developing therapies designed to fix the gene itself. View full story: https://www.biocentury.com/article/658810 #BiotechMarkets #EpilepsyResearch #Kv7 #RareDisease #GeneTherapy 00:00 - Introduction 03:23 - Market Sentiment 09:58 - Xenon Phase III Win 18:03 - Friedreich Ataxia Pipeline To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

17 mar

•

25 min
3 MAR

Ep. 352 - A Multipolar Biopharma World; Rare Disease Spotlight

Can a strong U.S. biopharma industry be reconciled with the successful emergence of China? And can China be a catalyst of positive change across the global industry, even if this implies some level of rebalancing away from the U.S.? On the latest BioCentury This Week podcast, BioCentury’s analysts discuss a Guest Commentary by McKinsey Senior Partner Emeritus Franck Le Deu, who argues that a multipolar biopharma world in which the U.S. continues to thrive even as China becomes meaningfully stronger can emerge. The analysts also discuss BioCentury’s latest Rare Disease Spotlight, which focuses on a wave of therapies aiming to activate retinal function in Stargardt disease patients. Turning to FDA, BioCentury Washington Editor Steve Usdin discusses recent public statements by FDA Commissioner Marty Makary, questions about Vinay Prasad’s future, and the plausible mechanism pathway. View full story: https://www.biocentury.com/article/658606 #GlobalBiopharma #ChinaBiotech #RareDisease #StargardtDisease #FDAPolicy 00:00 - Introduction 02:47 - Multipolar Biopharma World 13:39 - Rare Disease Spotlight 25:15 - Makary Remarks 31:14 - Plausible Mechanism Framework To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

3 mar

•

35 min
9 MAR

Ep. 353 - Prasad Departure and Future of Fibrosis Therapies

The second ousting of Vinay Prasad from FDA in the past eight months won’t lead to major changes at the agency, other than selecting a successor tasked with keeping FDA out of the news ahead of the coming midterm elections. On the latest BioCentury This Week podcast, Washington editor Steve Usdin lays out why the former CBER director was pushed out at FDA and what’s next for the agency following his departure. BioCentury’s editors also discuss the next wave of therapies for idiopathic pulmonary fibrosis, including whether new candidates might go beyond slowing disease to halt or even reverse progression, the biological complexity that makes fibrosis so challenging, and what the 20-plus Phase II programs could teach the field about fibrosis biology. Also up for discussion were recent clinical wins — as well as more complicated readouts — from psychedelic therapies; plus the latest data updates from obesity treatments, with a focus on amylin agonists. View full story: https://www.biocentury.com/article/658698 #FDA #IdiopathicPulmonaryFibrosis #PsychedelicTherapies #ObesityDrugs #AmylinAgonists 00:00 - Introduction 01:56 - Prasad's Departure 15:27 - Fibrosis Therapies 23:35 - Psychedelics Clinical Catalysts 28:24 - Obesity Updates To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

9 mar

•

37 min
24 FEB

Ep. 351 - Gilead's Arcellx Buy. Plus: ctDNA as Surrogate Endpoint

Gilead is acquiring Arcellx for $7.8 billion up front three years after forging a partnership with the biotech around a cell therapy for multiple myeloma. On the latest BioCentury This Week podcast, BioCentury’s analysts assess what the deal does for the Foster City, Calif.-based biotech’s pipeline. The analysts also discuss the case for using ctDNA as a surrogate endpoint for early cancer trials. Turning to Washington, Steve Usdin offers his takeaways from last week’s PhRMA Forum, which focused on China and the Trump administration’s most favored nation (MFN) drug pricing policy, and on the lessons that can be drawn from FDA’s about-face on the recent vaccine application from Moderna. View full story: https://www.biocentury.com/article/658516 #BiotechMA #MultipleMyeloma #ctDNA #DrugPricingPolicy #FDA 00:00 - Introduction 02:34 - Gilead's Arcellx Buy 11:14 - ctDNA Surrogate Endpoints 21:59 - PhRMA Forum Takeaways 29:19 - FDA Moderna U-turn To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

24 feb

•

35 min
23 ENE

Ep. 346 - 2026 Public Markets Preview

The biotech bull is back, and buysiders believe this market has staying power for the first time in nearly five years. On a special episode of the BioCentury This Week podcast, Director of Biopharma Intelligence Stephen Hansen and colleagues discuss Hansen’s 2026 Public Markets Preview, which found interest rates, policy in Washington and fundamentals finally aligning and a wave of launches and M&A that could keep capital flowing into the sector. View full story: https://www.biocentury.com/article/658154 #BiotechBullMarket #PublicMarkets #BiotechMA #IPOOutlook #FDApolicy 00:00 - Introduction 00:41 - Market Sentiment 07:55 - Biotech's Next Wave 14:47 - Lingering Concerns 23:29 - IPOs 26:47 - M&A To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

23 ene

•

31 min

BioCentury Podcasts leverage three decades of biopharma intelligence with thoughtful, accurate, and objective insights. BioCentury editors spotlight key scientific opinion leaders, corporate decision-makers, venture capitalists, and patient advocates, keeping you informed on the most current biotech stories and highlighting life science innovations.

Sitio web

BioCentury Podcasts

Top programas

Ep. 360 - FDA’s FIH plans. Plus: billion-dollar deals, funds

Ep. 359 - 2Q markets preview, tariffs and biotech takeouts

Ep. 358 - Europe's biotech challenge

Ep. 356 - Arrowhead’s arc. Plus: AI in biotech venture, Synnovation, MFN

Ep. 347 - Speeding China's Innovation. Plus: Neuro Catalysts and Newcos

Ep. 355 - Capital market mood, Xenon data, Friedreich ataxia pipeline

Ep. 352 - A Multipolar Biopharma World; Rare Disease Spotlight

Ep. 353 - Prasad Departure and Future of Fibrosis Therapies

Ep. 351 - Gilead's Arcellx Buy. Plus: ctDNA as Surrogate Endpoint

Ep. 346 - 2026 Public Markets Preview

Información

BioCentury Podcasts

Top programas

Top episodios

Información